Navigation Links
AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
Date:6/6/2009

Two-year study presented at the American Diabetes Association's 69th Scientific Sessions shows investigational product comparable to standard insulin therapy in pulmonary function tests

NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- AFRESA(R) (insulin human [rDNA origin]) Inhalation Powder is a well-tolerated, ultra rapid acting insulin with changes in pulmonary function tests comparable to usual antidiabetic treatment, according to data presented today at the American Diabetes Association's 69th Scientific Sessions. Results from the prospective, multicenter, phase 3 study conducted over a two-year period showed no difference in mean change in forced expiratory volume in one second (FEV(1)) between those treated with AFRESA and those treated with standard insulin therapy.

"Current mealtime insulin therapies, while accepted as an effective means to control glucose levels, have several limitations," said Peter Richardson, Corporate Vice President and Chief Scientific Officer, MannKind Corporation. "Our encouraging findings indicate that AFRESA may be a promising new treatment option with less weight gain and lower risk of hypoglycemia compared with current mealtime insulin therapy."

AFRESA is a novel, ultra rapid acting mealtime insulin therapy with an action profile that mimics meal-related early insulin release. Based on an extensive phase 3 clinical program, a New Drug Application (NDA) has been accepted by the U.S. Food and Drug Administration (FDA) requesting approval to market AFRESA Inhalation Powder and the AFRESA Inhaler for use in adult patients with type 1 and type 2 diabetes mellitus for the treatment of hyperglycemia. AFRESA is conveniently administered by oral inhalation.

Diabetes, which affects 23.6 million people in the U.S., or 8 percent of the population, is characterized by the body's inability to properly regulate levels of blood glucose, or blood sugar. Insulin, a hormone
'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
2. PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans
3. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
4. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
5. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
6. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
7. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
9. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
10. TNFerade(TM) Phase III Data Presented at ASCO
11. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... N.J., July 30, 2015 PTC Therapeutics, Inc. ... and reported financial results for the second quarter ending ... on many fronts across the organization.  We are excited ... muscular dystrophy clinical trial ever conducted with topline results ... Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is ...
(Date:7/30/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... the notice it received on May 21, 2015 from ... Company was below certain of the Exchange,s continued listing ... of the NYSE MKT Company Guide, due to the ...
(Date:7/30/2015)... Eisai Inc. announced today that regulatory applications ... , European Union and Japan ... eribulin, for the treatment of patients with inoperable soft ... advanced or metastatic disease. These regulatory ... Phase 3 clinical trial (Study 309), which met its ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
...   SAP America Inc., a subsidiary of ... SAP ), today introduced the SAP® Collaborative E-Care Management application ... the application aims to connect care providers, patients and their ... at HIMSS 2012 , being held February 20–24 in ...
... SurgLine International, Inc. (SGLN.PK). Thomas Toland, ... the past six months we have made certain public ... contracts and a pending acquisition in an effort to ... Our management team has completed an internal ...
Cached Medicine Technology:Newsbyte: SAP to Integrate Healthcare in the Community Through Collaborative Care 2SurgLine International, Inc. Update to Shareholders on Revenue Pipeline and Organizational Changes 2
(Date:7/30/2015)... ... ... Dale Sky Jones, Executive Chancellor of Oaksterdam University , the first cannabis ... at the Caribe Royal All Suites Hotel and Convention Center in Orlando, Florida, October ... medical cannabis expo in the country and this year’s expo will be the first ...
(Date:7/30/2015)... Ferry, New York (PRWEB) , ... July 31, 2015 , ... ... Barack Obama’s call to action by asking community members to contribute to the College’s ... on, “Helping more of our young people stay on track. Providing the support they ...
(Date:7/30/2015)... ... 30, 2015 , ... OSF Healthcare System has been recognized as ... Survey conducted by Hospitals & Health Networks. This marks the fourth consecutive year for ... The Sisters of the Third Order of St. Francis . , Health data security ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zaca ... on the go. With no water needed, the refreshing berry-flavored tablets are the ... to get the natural ingredients that may help with body detoxification, protection and ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... at ATA’s 21st Annual Meeting and Tradeshow focused exclusively on telemedicine, telehealth and ... cutting-edge health care technology vendors, will take place May 14-17, 2016 in Minneapolis, ...
Breaking Medicine News(10 mins):Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 4Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 5Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3
... gap is alive and well in heart disease, a new international ... to treatment in both heart attack and severe chest pain. ... twice as likely as men to have normal or mild results ... blockage taking up more than 50 percent of any one blood ...
... ... Flows Increase, BIRMINGHAM, Ala., May 6 HealthSouth,Corporation (NYSE: ... first quarter ended March 31, 2008. Compared to the,first quarter of ... net income increased by $76.4 million., "The results of the ...
... and,Mississippi still working to recover from the Hurricane Katrina ... Department of,Health and Human Services (HHS)., "HHS continues ... health care,problems created by Hurricane Katrina," Secretary Mike Leavitt ... make sure the citizens of these,states have continued access ...
... Today at 5:30 p.m. EDT, FRAZER, Pa., ... that a Joint Advisory Committee to the U.S. ... approval of an expanded,label for FENTORA(R) (fentanyl buccal ... opioid-tolerant patients with chronic pain conditions.,The panel expressed ...
... have shown for the first time that thrombopoietin (TPO), ... to increase platelet count in cancer patients during chemotherapy, ... heart attack. , The study, led by ... the division of cardiothoracic surgery, was published in the ...
... now register to attend TCT2008 (Transcatheter Cardiovascular Therapeutics), ... Foundation. TCT gathers leading medical researchers and clinicians ... developments in the field of interventional cardiology and ... state-of-the-art techniques and training to interventional cardiologists around ...
Cached Medicine News:Health News:Women and heart attack: Study finds failure to recognize symptoms, failure to treat appropriately 2Health News:Women and heart attack: Study finds failure to recognize symptoms, failure to treat appropriately 3Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 2Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 3Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 4Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 5Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 6Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 7Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 8Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 9Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 10Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 11Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 12Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 13Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 14Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 15Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 16Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 17Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 18Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 19Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 20Health News:HealthSouth Reports Results for First Quarter Ended March 31, 2008 21Health News:Hospitals in Louisiana and Mississippi to Receive More Katrina Recovery Grants 2Health News:Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 2Health News:Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 3Health News:Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 4Health News:Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 5Health News:Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA 6Health News:Naturally-occuring protein may be effective in limiting heart attack injury and restoring function 2Health News:Media registration now open for TCT2008 2
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Cross action, round handle, maximum opening 2.8 mm....
Dodick nucleus cracker cross-action longitudinally serrated paddle shaped jaws for cracking the nucleus through a 3.0 mm incision....
Irrigating nucleus chopper, 1.5 mm long wedge-shaped, inferior edge with round end, 0.6 mm dual sideports 20 gauge....
Medicine Products: